Seamac Formulations Profile
Key Indicators
- Authorised Capital ₹ 4.00 M
as on 04-06-2024
- Paid Up Capital ₹ 4.00 M
as on 04-06-2024
- Company Age 17 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.52 Cr
as on 04-06-2024
- Satisfied Charges ₹ 1.50 M
as on 04-06-2024
- Revenue 3.87%
(FY 2023)
- Profit -63.49%
(FY 2023)
- Ebitda 99.67%
(FY 2023)
- Net Worth 2.30%
(FY 2023)
- Total Assets 33.16%
(FY 2023)
About Seamac Formulations
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.00 M and a paid-up capital of Rs 4.00 M.
The company currently has active open charges totaling ₹1.52 Cr. The company has closed loans amounting to ₹1.50 M, as per Ministry of Corporate Affairs (MCA) records.
Sudhir Sharma and Abhishek Sharma serve as directors at the Company.
- CIN/LLPIN
U24232PB2007PTC030836
- Company No.
030836
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Jan 2007
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Hoshiarpur, Punjab, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Seamac Formulations?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sudhir Sharma  | Director | 15-Feb-2007 | Current |
| Abhishek Sharma | Additional Director | 20-May-2019 | Current |
Financial Performance of Seamac Formulations.
Seamac Formulations Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 3.87% increase. The company also saw a substantial fall in profitability, with a 63.49% decrease in profit. The company's net worth moved up by a moderate rise of 2.3%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Seamac Formulations?
Unlock access to Seamac Formulations's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Seamac India Pharmaceuticals Private LimitedActive 30 years 6 monthsSudhir Sharma and Abhishek Sharma are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 09 Jan 2023 | ₹1.00 M | Open |
Others Creation Date: 29 Sep 2021 | ₹5.00 M | Open |
Others Creation Date: 25 Jun 2020 | ₹0.50 M | Open |
How Many Employees Work at Seamac Formulations?
Unlock and access historical data on people associated with Seamac Formulations, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Seamac Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Seamac Formulations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
